Business
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
SEATTLE, December 24, 2025--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the e
About this update from Omeros Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":342,"url":"https://media.zenfs.com/en/business-wire.com/895c64b7f4bef17e7361cbca89e0eb3c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EB0BclXuUbGS5KfOiapGIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/895c64b7f4bef17e7361cbca89e0eb3c","width":480,"height":342}},"lazy":false},{"type":"text","content":"– Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET –","length":76,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older.","length":226,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence.","length":324,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strong survival benefit: 100-day survival from TA-TMA diagnosis, based on all-cause mortality, was 73% in the pivotal trial and 74% in evaluable EAP patients; all patients met international harmonization criteria for high-risk TA-TMA.","length":234,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Safety profile and Prescribing Information highlights: The only approved TA-TMA therapy, YARTEMLEA has no Boxed Warning and no Risk Evaluation and Mitigation Strategy (REMS), and vaccinations are not required prior to treatment. Serious infections and other adverse reactions, regardless of causality, have occurred in patients treated with YARTEMLEA; see Important Safety Information for details.","length":397,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1181,"olType":false},{"type":"text","content":"SEATTLE, December 24, 2025--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administra...